05:13:46 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


Inhalation Sciences Sweden, ISAB, är ett forskningsbolag. Idag innehas störst fokus mot framställning och utvecklande av laboratorieinstrument. Instrumenten används för att mäta partiklar i inandningsluften och hur luftens sammansättning påverkar lungorna. Bolaget säljer produkter under varierade varumärken, främst på den europeiska marknaden. Inhalation Sciences Sweden grundades 2004 och har sitt huvudkontor i Huddinge.


2022-11-22 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-06-08 Ordinarie utdelning ISAB 0.00 SEK
2022-05-23 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-28 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-06-22 Extra Bolagsstämma 2021
2021-06-09 Ordinarie utdelning ISAB 0.00 SEK
2021-06-08 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-12 Extra Bolagsstämma 2020
2020-05-13 Ordinarie utdelning ISAB 0.00 SEK
2020-05-12 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-22 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning ISAB 0.00 SEK
2019-02-21 Bokslutskommuniké 2018
2018-12-13 Extra Bolagsstämma 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-24 Ordinarie utdelning ISAB 0.00 SEK
2018-05-23 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-02-22 Bokslutskommuniké 2017
2017-11-17 Kvartalsrapport 2017-Q3
2017-08-28 Kvartalsrapport 2017-Q2
2021-11-19 09:21:33

(Stockholm, 19 November 2021) The Institute of Environmental Medicine (IMM) at Karolinska Institutet has extended its lease of ISAB's aerosol generation platform PreciseInhale[ ][®]. The extended lease lasts for the first half of 2022 and includes ISAB's innovative new in vivo module for aerosol exposures to guinea pigs. IMM is one of the world's most innovative pulmonary research bodies, and a returning ISAB customer. The original agreement was signed and announced in March 2020.

The extended lease includes ISAB's new in vivo module for aerosol exposures to guinea pigs. Guinea pigs are a highly relevant test subjects for inhalation studies. Human and guinea pigs share many similarities in lung anatomy, physiology, pharmacology, particularly airway autonomic control and response to allergens.

The new module employs ISAB's unique one-animal-at-a-time precision dosing method - with single animals being gently dosed through a controlled exposure, generating high-precision data and reducing the need for large numbers of test animals. The guinea pig module is attracting interest from several other customers.

The extended lease is between ISAB and IMM Associate Professor Mikael Adner, Head of the Unit for Experimental Asthma and Allergy Research, a leading expert in pulmonary research and the author of over 100 peer-reviewed papers. Assoc Professor Adner: "We have recently developed a unique guinea pig asthma model where we use relevant allergens and exposure through the airways. With the PreciseInhale[®] we will be able to deliver aerosol with even lung distribution that also reaches the peripheral parts. This will be an important tool in our asthma research. "

ISAB CEO Manoush Masarrat: "Karolinska Institutet is a much-valued, long-term customer and we are pleased to continue our agreement with them. The fact that customers of this calibre keep returning speaks clearly to the exceptional value and precision of our tools."